Don’t Ignore Your Kidneys: Early Action Can Slow CKD
January 19, 2026
Brand Name :
N/A
Synonyms :
lestaurtinib
Class :
Tyrosine Kinase Inhibitors
Dosage Forms & Strengths
Tablet
60mg
80mg
Take an initial dose of 60 mg orally twice daily for 8 weeks
Not determined
Refer adult dosing
Action and spectrum:
The type III receptor tyrosine kinase FMS-like tyrosine kinase 3 (FLT3) is target AML.
FLT3 is important in the development of normal multipotent stem cells and B cells.
Frequency not defined
Diarrhea
Nausea
Vomiting
Black box warning:
None
Contraindications/caution:
Hypersensitivity
Severe Hepatic Impairment
Pregnancy Warnings:
Pregnancy category: N/A
Lactation:
Excretion of the drug into the human breast milk is unknown
Pregnancy categories:
Category A: Satisfactory and well-controlled studies show no evidence of risk to the fetus in the first trimester or in the later trimester.
Category B: No evidence of risk to fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women.
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category clearly outweigh risks over benefits. These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Administration:
Oral administration
It is administered as oral dosage form.
Patient information leaflet
Generic Name: lestaurtinib
Why do we use lestaurtinib?
lestaurtinib indicated in the treatment of acute myeloid leukemia (AML) and hematological malignancies.